Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)

Detalhes bibliográficos
Autor(a) principal: Miranda, AC
Data de Publicação: 2020
Outros Autores: Mendez, J, Serrão, R, Vale, F, Manata, MJ, Pinto, S, Gomes, A, Valente, C, Pacheco, P, Pazos, R, Pereira, R, Martins, A, Germano, I, Rocha, S, Reis, AP, Sarmento-Castro, R
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/4046
Resumo: Direct-acting antiviral drugs (DAAs) have recently changed the paradigm of hepatitis C therapy, significantly improving treatment response rates, patient life expectancy and quality of life. In Portugal, sofosbuvir (SOF) and SOF/ledipasvir (SOF/LDV) were fully reimbursed by the National Health System since early 2015 and generalized use of interferon-free DAA based regimens became current practice. During 2016, the remaining DAAs were sequentially added and covered by the same health access policy. The Portuguese Study Group of Hepatitis and HIV Co-infection (GEPCOI) collected data from 15 clinical centres in Portugal, pertaining to the HCV treatment experience with DAA regimens. A cohort of 2133 patients was analysed, representing one of the largest DAA treated HCV/HIV co-infected individuals. The global sustained virologic response (SVR) achieved was 95% in this real-life cohort setting. Linear regression analysis showed significant differences in treatment response rates when using SOF plus ribavirin (RBV) combination in genotype 2 or 3 infected individuals (P < .002) and in those with liver cirrhosis (P < .002). These findings corroborate that early treatment is mandatory in HIV/HCV co-infected patients, as response rates may be negatively influenced by higher fibrosis stages and suboptimal DAA regimens. The current national Portuguese health policy should continue to promote wider treatment access and individualized therapy strategies, aiming at the elimination of HCV infection in this high-risk co-infected population.
id RCAP_b345f390fc675fbeea4eb6d0ceaa068d
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/4046
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)HCC INFAdultAgedFemaleAntiviral Agents* / therapeutic useMaleMiddle AgedCoinfection* / drug therapyDrug Therapy, CombinationGenotypeHIV Infections* / drug therapyHepacivirusHepatitis C, Chronic* / drug therapyHumansNigeriaPortugalQuality of LifeYoung AdultSofosbuvir / therapeutic useTreatment OutcomeDirect-acting antiviral drugs (DAAs) have recently changed the paradigm of hepatitis C therapy, significantly improving treatment response rates, patient life expectancy and quality of life. In Portugal, sofosbuvir (SOF) and SOF/ledipasvir (SOF/LDV) were fully reimbursed by the National Health System since early 2015 and generalized use of interferon-free DAA based regimens became current practice. During 2016, the remaining DAAs were sequentially added and covered by the same health access policy. The Portuguese Study Group of Hepatitis and HIV Co-infection (GEPCOI) collected data from 15 clinical centres in Portugal, pertaining to the HCV treatment experience with DAA regimens. A cohort of 2133 patients was analysed, representing one of the largest DAA treated HCV/HIV co-infected individuals. The global sustained virologic response (SVR) achieved was 95% in this real-life cohort setting. Linear regression analysis showed significant differences in treatment response rates when using SOF plus ribavirin (RBV) combination in genotype 2 or 3 infected individuals (P < .002) and in those with liver cirrhosis (P < .002). These findings corroborate that early treatment is mandatory in HIV/HCV co-infected patients, as response rates may be negatively influenced by higher fibrosis stages and suboptimal DAA regimens. The current national Portuguese health policy should continue to promote wider treatment access and individualized therapy strategies, aiming at the elimination of HCV infection in this high-risk co-infected population.WileyRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEMiranda, ACMendez, JSerrão, RVale, FManata, MJPinto, SGomes, AValente, CPacheco, PPazos, RPereira, RMartins, AGermano, IRocha, SReis, APSarmento-Castro, R2022-04-22T15:02:24Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4046engJ Viral Hepat. 2020 Jul;27(7):715-720.10.1111/jvh.13281.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:45:03Zoai:repositorio.chlc.min-saude.pt:10400.17/4046Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:21:21.285260Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
title Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
spellingShingle Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
Miranda, AC
HCC INF
Adult
Aged
Female
Antiviral Agents* / therapeutic use
Male
Middle Aged
Coinfection* / drug therapy
Drug Therapy, Combination
Genotype
HIV Infections* / drug therapy
Hepacivirus
Hepatitis C, Chronic* / drug therapy
Humans
Nigeria
Portugal
Quality of Life
Young Adult
Sofosbuvir / therapeutic use
Treatment Outcome
title_short Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
title_full Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
title_fullStr Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
title_full_unstemmed Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
title_sort Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)
author Miranda, AC
author_facet Miranda, AC
Mendez, J
Serrão, R
Vale, F
Manata, MJ
Pinto, S
Gomes, A
Valente, C
Pacheco, P
Pazos, R
Pereira, R
Martins, A
Germano, I
Rocha, S
Reis, AP
Sarmento-Castro, R
author_role author
author2 Mendez, J
Serrão, R
Vale, F
Manata, MJ
Pinto, S
Gomes, A
Valente, C
Pacheco, P
Pazos, R
Pereira, R
Martins, A
Germano, I
Rocha, S
Reis, AP
Sarmento-Castro, R
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Miranda, AC
Mendez, J
Serrão, R
Vale, F
Manata, MJ
Pinto, S
Gomes, A
Valente, C
Pacheco, P
Pazos, R
Pereira, R
Martins, A
Germano, I
Rocha, S
Reis, AP
Sarmento-Castro, R
dc.subject.por.fl_str_mv HCC INF
Adult
Aged
Female
Antiviral Agents* / therapeutic use
Male
Middle Aged
Coinfection* / drug therapy
Drug Therapy, Combination
Genotype
HIV Infections* / drug therapy
Hepacivirus
Hepatitis C, Chronic* / drug therapy
Humans
Nigeria
Portugal
Quality of Life
Young Adult
Sofosbuvir / therapeutic use
Treatment Outcome
topic HCC INF
Adult
Aged
Female
Antiviral Agents* / therapeutic use
Male
Middle Aged
Coinfection* / drug therapy
Drug Therapy, Combination
Genotype
HIV Infections* / drug therapy
Hepacivirus
Hepatitis C, Chronic* / drug therapy
Humans
Nigeria
Portugal
Quality of Life
Young Adult
Sofosbuvir / therapeutic use
Treatment Outcome
description Direct-acting antiviral drugs (DAAs) have recently changed the paradigm of hepatitis C therapy, significantly improving treatment response rates, patient life expectancy and quality of life. In Portugal, sofosbuvir (SOF) and SOF/ledipasvir (SOF/LDV) were fully reimbursed by the National Health System since early 2015 and generalized use of interferon-free DAA based regimens became current practice. During 2016, the remaining DAAs were sequentially added and covered by the same health access policy. The Portuguese Study Group of Hepatitis and HIV Co-infection (GEPCOI) collected data from 15 clinical centres in Portugal, pertaining to the HCV treatment experience with DAA regimens. A cohort of 2133 patients was analysed, representing one of the largest DAA treated HCV/HIV co-infected individuals. The global sustained virologic response (SVR) achieved was 95% in this real-life cohort setting. Linear regression analysis showed significant differences in treatment response rates when using SOF plus ribavirin (RBV) combination in genotype 2 or 3 infected individuals (P < .002) and in those with liver cirrhosis (P < .002). These findings corroborate that early treatment is mandatory in HIV/HCV co-infected patients, as response rates may be negatively influenced by higher fibrosis stages and suboptimal DAA regimens. The current national Portuguese health policy should continue to promote wider treatment access and individualized therapy strategies, aiming at the elimination of HCV infection in this high-risk co-infected population.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2022-04-22T15:02:24Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4046
url http://hdl.handle.net/10400.17/4046
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv J Viral Hepat. 2020 Jul;27(7):715-720.
10.1111/jvh.13281.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131309323321344